Campath
(Alemtuzumab)ApprovedMonoclonal antibody
Alemtuzumab is used to treat certain types of blood cancers (like chronic lymphocytic leukemia) and relapsing-remitting multiple sclerosis by targeting and destroying specific immune cells in the body.[2] Campath is currently approved and in use across 59 indications[4].[1]
Campath is one of 1005 small molecule programs targeting Peritoneum Cancer. It is currently in Approved.
59
Indications
204
Total Trials
29
Active Trials
1,004
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 59 indications
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Campath
GGenzyme, a Sanofi Company
Approved
Velban
EEastern Cooperative Oncology Group
Preclinical
Oncaspar
SServier
Preclinical
Zofran
NovartisPreclinical
Tafasitamab
IncytePreclinical
Nuvigil
NNuvo Research GmbH
Preclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
PEG-Intron
Merck & Co.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Lymphocytic Leukemia31 trials
Show 28 more trials
Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)
Terminated·—·Phase 1·NCT00947388·9 enrolled
Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete Remission
Completed·—·Phase 2·NCT00458523·54 enrolled
Compassionate Use of Campath-1H in Treating Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic Leukemia
Completed·—·N/A·NCT00021151·2 enrolled
Allogeneic Stem Cell Transplantation in Chronic Lymphocytic Leukemia
Unknown status·—·Phase 2·NCT00337519·82 enrolled
Lymphoma14 trials
Show 11 more trials
Cyclophosphamide and Alemtuzumab In Lymphoma
Terminated·—·Phase 1·NCT03132584·3 enrolled
Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma
Unknown status·—·Phase 1/2·NCT00363090·84 enrolled
Multiple Sclerosis12 trials
Show 9 more trials
High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment
Terminated·—·Phase 2·NCT01679041·1 enrolled
Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis
Terminated·—·Phase 1/2·NCT01712945·40 enrolled
Sickle Cell Disease11 trials
TMLI and Alemtuzumab for Treatment of Sickle Cell Disease
Active, not recruiting·—·Phase 1·NCT05384756·2 enrolled
Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia
Active, not recruiting·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 1/2·NCT05357482·40 enrolled
Show 8 more trials
Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease
Active, not recruiting·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 1/2·NCT03077542·57 enrolled
Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody
Recruiting·—·Phase 2·NCT06358638·12 enrolled
Stem Cell Transplant in Sickle Cell Disease and Thalassemia
Active, not recruiting·—·Phase 2·NCT00408447·53 enrolled
Stem Cell Transplant9 trials
Show 6 more trials
87 more indications
Kidney Transplant6 trials
Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00240994·35 enrolled
Simultaneous Pancreas-kidney Transplantation With Campath Protocol
Completed·—·Phase 3·NCT00316810·30 enrolled
Show 3 more trials
Treatment of Children With Kidney Transplants by Injection of CD4+CD25+FoxP3+ T Cells to Prevent Organ Rejection
Unknown status·PPirogov Russian National Research Medical University·Phase 1/2·NCT01446484·30 enrolled
Bone Marrow Transplantation5 trials
Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias
Unknown status·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 1/2·NCT00061568·130 enrolled
Show 2 more trials
Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita
Active, not recruiting·—·Phase 2·NCT01659606·40 enrolled
Acute Lymphoblastic Leukemia5 trials
Allogeneic Stem Cell Transplantation4 trials
Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies
Completed·—·Phase 2·NCT00153985·2 enrolled
Show 1 more trial
Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases
Completed·—·Phase 2/3·NCT01019876·38 enrolled
Leukemia3 trials
Severe Aplastic Anemia3 trials
Phase II2 trials
SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCD
Terminated·—·Phase 2·NCT02013375·2 enrolled
CLL2 trials
Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL
Terminated·—·Phase 2·NCT01465334·30 enrolled
Mycosis Fungoides2 trials
Anemia2 trials
Haploidentical PBMC Transplant for Severe Congenital Anemias
Active, not recruiting·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 1/2·NCT00977691·23 enrolled
Transplantation2 trials
Chronic Granulomatous Disease2 trials
Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists
Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT05463133·50 enrolled
Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease
Completed·—·Phase 2·NCT00578643·15 enrolled
Hemoglobinopathies2 trials
Hematological Malignancies2 trials
Methylprednisolone2 trials
Campath-1H + FK506 and Methylprednisolone for GVHD
Completed·—·Phase 2·NCT00109993·34 enrolled
Myelodysplastic Syndrome2 trials
Hematopoietic Stem Cell Transplant2 trials
Islet Transplantation2 trials
Non-malignant Disorders2 trials
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
Terminated·—·Phase 1/2·NCT00801931·1 enrolled
Allogeneic Hematopoietic Cell Transplant2 trials
Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation
Recruiting·—·Phase 2·NCT05501756·60 enrolled
Primary Peritoneal Cancer1 trial
Renal Cell Carcinoma1 trial
Stem Cell Transplantation1 trial
Myelodysplastic Syndromes1 trial
Cytomegalovirus Infection1 trial
Acute Lymphoblastic Leukaemia1 trial
Type 1 Diabetes1 trial
Bone Marrow Failure1 trial
Refractory1 trial
Relapse1 trial
Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL
Completed·—·Phase 1·NCT00330252·29 enrolled
Pregnancy1 trial
Efficacy1 trial
Suicide1 trial
Conditioning1 trial
Tolerance1 trial
Belatacept Post Depletional Repopulation to Facilitate Tolerance
Completed·—·Phase 2·NCT00565773·40 enrolled
Immunosuppression1 trial
Prolymphocytic Leukemia1 trial
Relapsed or Refractory1 trial
Hematopoietic Stem Cell Transplantation1 trial
Residual Disease1 trial
T Cell1 trial
Do Alemtuzumab Levels Predict T Cell Chimerism After MSD SCT for SCD?
Unknown status·—··NCT05905770·20 enrolled
Chronic GVHD1 trial
Campath in Chronic GVHD
Completed·—·Phase 1·NCT00495755·13 enrolled
Risk Stratification1 trial
Hodgkin's Disease1 trial
Chronic Inflammatory Demyelinating Polyradiculoneuropathy1 trial
Relapsing-Remitting Multiple Sclerosis1 trial
Inclusion Body Myositis1 trial
Alemtuzumab to Treat Sporadic Inclusion Body Myositis
Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 2·NCT00079768·20 enrolled
T-cell acute lymphoblastic leukemia1 trial
Langerhans Cell Histiocytosis1 trial
Neurodegeneration1 trial
Gene Therapy1 trial
Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study
Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT06959771·1 enrolled
Graft Rejection1 trial
Effectiveness and Safety of Campath in Combination With Tacrolimus Monotherapy to Prevent Kidney Graft Rejection
Completed·—·Phase 3·NCT00147381·197 enrolled
Vasculitis1 trial
Alemtuzumab for ANCA Associated Refractory Vasculitis
Unknown status·—·Phase 4·NCT01405807·24 enrolled
Liver Transplant1 trial
Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00105235·27 enrolled
Peripheral Blood Stem Cell Transplantation1 trial
Graft Vs Host Disease1 trial
Immunodeficiency1 trial
Homeostasis1 trial
Tolerance by Engaging Antigen During Cellular Homeostasis
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT03504241·8 enrolled
Renal Transplantation1 trial
Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation
Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT01436305·19 enrolled
Dexamethasone1 trial
Autologous Hematopoietic Stem Cell Transplantation1 trial
Intestinal Transplantation1 trial
Renal Transplant Recipients1 trial
T-Cell Prolymphocytic Leukemia1 trial
Recessive Dystrophic Epidermolysis Bullosa1 trial
Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Terminated·—·Phase 1·NCT00881556·3 enrolled
Mantle Cell Lymphoma1 trial
Newly Diagnosed1 trial
Dyskeratosis Congenita1 trial
Unspecified2 trials
Precision Dosing of Alemtuzumab
Completed·—·N/A·NCT03302754·12 enrolled
Regulatory
FDA Approval Timeline[5]
May 7, 2001
CAMPATH
BLA BLA103948
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Campath drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Alemtuzumab. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- CAMPATH-1 Antigen Inhibitor[3]
- Modality
- Monoclonal antibody[3]
- Highest Phase
- Approved[1]
- Company
- GGenzyme, a Sanofi Company